Diagnostic Value of Plateletâ€“To-Lymphocyte Ratio in Prostate Cancer

Kharisma Prasetya Adhyatma; Syah Mirsya Warli

doi:10.3889/oamjms.2019.252

Authors

Kharisma Prasetya Adhyatma Department of Urology, Faculty of Medicine, Sumatera Utara University, Adam Malik Hospital, Medan, Indonesia
Syah Mirsya Warli Department of Urology, Faculty of Medicine, Sumatera Utara University, Adam Malik Hospital, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.252

Keywords:

Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, Diagnostic, Prostate cancer

Abstract

BACKGROUND: Previous studies demonstrated the promising value of platelet-to-lymphocyte (PLR) in prostate cancer.

AIM: This study was conducted to evaluate its pre-biopsy values in predicting prostate cancer.

METHODS: We included all benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who underwent a prostate biopsy in Adam Malik Hospital between August 11th 2011 and August 31st 2015. The relationship between pre-biopsy variables which could be affecting the percentage of prostate cancer risk was evaluated, including age, prostate-specific antigen (PSA) level, and prostate volume (EPV). The PLR was calculated from the ratio of related platelets with their absolute lymphocyte counts. The values then analysed to evaluate their associations with the diagnosis of BPH and PCa.

RESULTS: As many as 298 patients consisted of 126 (42.3%) BPH and 172 PCa (57.7%) patients are included in this study. Mean age for both groups are 66.36 Â± 7.53 and 67.99 Â± 7.48 years old (p = 0.64), respectively. There are statistically significant differences noted from PSA (19.28 Â± 27.11 vs 40.19 Â± 49.39), EPV (49.39 Â± 23.51 vs 58.10 Â± 30.54), PLR (160.27 Â± 98.96 vs 169.55 Â± 78.07), and NLR (3.57 Â± 3.23 vs 4.22 Â± 2.59) features of both groups (p < 0.05). The AUC of PLR is 57.9% with a sensitivity of 56.4% and specificity of 55.6% in the cut-off point of 143 (p = 0.02). Besides, the NLR cut-off point of 3.08 gives 62.8% AUC with 64.5% sensitivity and 63.5% specificity. We asked for permission from the preceding authors of Indonesian Prostate Cancer Risk Calculator (IPCRC) and calculated its value from 98 randomised patients consist of 45 (45.92%) BPH and 53 (54.08%) PCa. We found a comparable value between PLR/NLR with IPCRC in predicting prostate cancer (AUC of 67.6%, 75.3%, and 68.4%, respectively) with a statistically significant difference of all value in both groups (p < 0.05).

CONCLUSIONS: PLR gives promising value in predicting prostate cancer in suspected patients. We suggest a further prospective study to validate its diagnostic values so it can be used as applicable routine calculation.